Early hidradenitis suppurativa diagnosis impact on long-term disease severity and treatment outcomes

Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatologic condition that causes debilitating pain and progressive disfiguration. Despite increased awareness and treatment options, diagnostic delays remain common and may significantly impact disease trajectory and patient outcomes. This review aims to evaluate how early diagnosis of HS influences long-term disease severity, comorbidity burden, and overall treatment outcomes. This narrative review was conducted using PubMed, including studies published from 2015 onward. Keywords such as “hidradenitis suppurativa,” “delay in diagnosis,” “severity,” and “outcomes” were used. After screening 1,436 records and applying inclusion criteria, 13 studies were selected for final analysis. Findings demonstrated that early diagnosis of HS is associated with reduced disease severity, fewer systemic and dermatologic comorbidities, and improved treatment responsiveness. Early recognition was linked to better physical, psychological, and socioeconomic outcomes. Quality of life was significantly impaired in patients with advanced disease, with higher DLQI scores and increased missed work days. Early diagnosis of HS is not only a clinical milestone but is associated with improvement of long-term outcomes. Prompt recognition and intervention are associated with reduced systemic inflammation, improved therapeutic efficacy, and lower psychosocial and economic burden of the disease. These findings underscore the urgent need for standardized diagnostic pathways and continued research into early identification strategies.